SCHEMBL1788970

SCHEMBL1788970

O=C(Nc1cccc(-c2nc3ccccn3c2-c2ccnc(Nc3cccc(C4CCNC4)c3)n2)c1)N1CCCc2ccccc21

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 15/20 0.52
BRAF P15056 4/20 0.50
INSR P06213 4/20 0.45
MAPK14 Q16539 1/20 0.45
EGFR P00533 4/20 0.43
ERBB2 P04626 4/20 0.43
PRKD3 O94806 3/20 0.41
LCK P06239 3/20 0.41
KIT P10721 3/20 0.41
FGFR1 P11362 3/20 0.41
SRC P12931 3/20 0.41
KDR P35968 3/20 0.41
SYK P43405 3/20 0.41
TAOK1 Q7L7X3 3/20 0.41
AURKB Q96GD4 3/20 0.41
SLK Q9H2G2 3/20 0.41
MAP3K20 Q9NYL2 3/20 0.41
MAP4K5 Q9Y4K4 3/20 0.41
AURKA O14965 2/20 0.41
MAP4K4 O95819 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1789429 0.97 IGF1R (0.52) IGF1RBRAFINSRMAPK14EGFR
SCHEMBL1789281 0.93 BRAF (0.53) IGF1RBRAFINSRMAPK14EGFR
SCHEMBL1786853 0.92 BRAF (0.54) IGF1RBRAFINSRMAPK14EGFR
SCHEMBL1786574 0.88 BRAF (0.55) IGF1RBRAFINSRMAPK14EGFR
SCHEMBL1789119 0.83 BRAF (0.51) IGF1RBRAFINSRMAPK14EGFR
SCHEMBL1788781 0.81 BRAF (0.56) IGF1RBRAFINSRMAPK14EGFR
SCHEMBL1787446 0.79 BRAF (0.58) IGF1RBRAFINSRMAPK14EGFR
SCHEMBL1789877 0.79 EGFR (0.60) IGF1RBRAFINSRMAPK14EGFR
SCHEMBL1788316 0.79 IGF1R (0.55) IGF1RBRAFINSRMAPK14EGFR
SCHEMBL1787261 0.79 BRAF (0.59) IGF1RBRAFINSREGFRERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9051315-B2 Imidazopyridines as a novel scaffold for multi-targeted kinase inhibition ABBVIE INC. (US) 2015-06-09 US claimed
EP-2496574-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION Abbott Laboratories (US) 2012-09-12 EP claimed
US-20110124632-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION ABBOTT LABORATORIES (US) 2011-05-26 US claimed
WO-2011053476-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION ABBOTT LABORATORIES (US) 2011-05-05 WO claimed
US-9051315-B2 Imidazopyridines as a novel scaffold for multi-targeted kinase inhibition ABBVIE INC. (US) 2015-06-09 US disclosed
EP-2496574-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION Abbott Laboratories (US) 2012-09-12 EP disclosed
US-20110124632-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION ABBOTT LABORATORIES (US) 2011-05-26 US disclosed
WO-2011053476-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION ABBOTT LABORATORIES (US) 2011-05-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124632-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION PACSIN2, MAP4K2, MAP3K6 IGF1R 937/4885BRAF 226/4885INSR 1243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.